Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Cytodyn Inc's Business Segments
Cytodyn Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Single Reportable Segment
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Single Reportable Segment0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Single Reportable Segment0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | - | - |
Description of Cytodyn Inc
CytoDyn Inc. is a biotechnology company that focuses on the development of innovative therapies for the treatment of cancer and immune disorders. The company is headquartered in Vancouver, Washington, and was founded in 200
CytoDyn's lead product, leronlimab (PRO 140), is a monoclonal antibody that targets the CCR5 receptor, which is a protein found on the surface of certain immune cells. CCR5 is involved in the regulation of the immune system, and blocking the receptor has been shown to be effective in treating a variety of diseases, including HIV, cancers, and autoimmune disorders.
Leronlimab has been granted fast-track designation by the U.S. Food and Drug Administration (FDA) for HIV and metastatic triple-negative breast cancer, and has also received orphan drug designation for glioblastoma, a type of brain cancer. The drug is currently in clinical trials for a range of indications, including breast cancer, COVID-19, and NASH (non-alcoholic steatohepatitis).
CytoDyn also has a pipeline of other CCR5-targeting drugs in various stages of development, including Cytolin, a combination therapy for HIV, and CCR5-Delta 32 Stem Cell Therapy, a potentially curative gene therapy for HIV.
In addition to its clinical development programs, CytoDyn also has collaborations with other pharmaceutical companies, research institutions, and government agencies to develop new therapies for a variety of diseases.
Overall, CytoDyn is a promising biotech company that is focused on developing innovative therapies for the treatment of challenging diseases. Its lead product, leronlimab, has shown significant promise in clinical trials, and the company is well-positioned to continue advancing its pipeline of CCR5-targeting drugs.
CytoDyn's lead product, leronlimab (PRO 140), is a monoclonal antibody that targets the CCR5 receptor, which is a protein found on the surface of certain immune cells. CCR5 is involved in the regulation of the immune system, and blocking the receptor has been shown to be effective in treating a variety of diseases, including HIV, cancers, and autoimmune disorders.
Leronlimab has been granted fast-track designation by the U.S. Food and Drug Administration (FDA) for HIV and metastatic triple-negative breast cancer, and has also received orphan drug designation for glioblastoma, a type of brain cancer. The drug is currently in clinical trials for a range of indications, including breast cancer, COVID-19, and NASH (non-alcoholic steatohepatitis).
CytoDyn also has a pipeline of other CCR5-targeting drugs in various stages of development, including Cytolin, a combination therapy for HIV, and CCR5-Delta 32 Stem Cell Therapy, a potentially curative gene therapy for HIV.
In addition to its clinical development programs, CytoDyn also has collaborations with other pharmaceutical companies, research institutions, and government agencies to develop new therapies for a variety of diseases.
Overall, CytoDyn is a promising biotech company that is focused on developing innovative therapies for the treatment of challenging diseases. Its lead product, leronlimab, has shown significant promise in clinical trials, and the company is well-positioned to continue advancing its pipeline of CCR5-targeting drugs.
CytoDyn Inc. is a biotechnology company that focuses on the discovery, development, and commercialization of innovative treatments for various medical conditions, particularly in the areas of HIV/AIDS, oncology, and autoimmune diseases. Their extensive offerings can be categorized into segments, products, and services, each designed to address specific health challenges and advance medical care.
Segments
1. HIV/AIDS:
This segment is primarily engaged in the development of immunotherapy drugs aimed at curing HIV infection. The focus is on targeting and neutralizing HIV-infected cells, thereby improving patient outcomes and quality of life for those living with the virus.
2. Oncology:
CytoDyns oncology segment specializes in immunotherapies targeting various types of cancer, including but not limited to breast cancer, pancreatic cancer, and colorectal cancer. The overarching goal is to develop treatments that enhance the bodys immune response against tumors, thereby potentially reducing cancer metastasis and improving survival rates.
3. Immunology:
This segment is dedicated to addressing autoimmune diseases, which occur when the immune system mistakenly attacks healthy cells. CytoDyn aims to develop therapies for conditions such as Crohns disease, psoriasis, and multiple sclerosis, focusing on modulating the immune response to alleviate symptoms and prevent disease progression.
Products
1. PRO 140:
PRO 140 is a unique monoclonal antibody designed to target and block the CCR5 receptor found on T-cells. This mechanism is significant because the CCR5 receptor is utilized by HIV to enter and infect these immune cells. By inhibiting this entry pathway, PRO 140 has the potential to serve as a therapeutic option for managing HIV infection. As of now, it is undergoing phase III clinical trials to assess its efficacy and safety in treating HIV.
2. Leronlimab:
Leronlimab is another monoclonal antibody from CytoDyn that specifically blocks the CCR5 receptor, but in this context, it is aimed at cancer treatment. By inhibiting the receptors activity in cancer cells, Leronlimab seeks to prevent their growth and spread, offering a promising avenue for cancer care. It is currently in phase II clinical trials for various malignancies.
3. CytoFLEX:
CytoFLEX represents an advanced flow cytometry technology developed by CytoDyn, enabling the simultaneous analysis of up to 13 different parameters at high speed. This capability is vital for single-cell analysis in clinical research, allowing for intricate insights into cellular behaviors and responses in various health conditions.
Services
1. Contract Manufacturing:
CytoDyn provides contract manufacturing services to produce clinical-grade monoclonal antibodies and proteins. Their offerings in this area include a full spectrum of services from product formulation and optimization through to scaling up for larger production needs, supporting both clinical and research applications.
2. Diagnostic Testing:
The company also offers diagnostic testing services for various infectious diseases, employing sophisticated flow cytometry technology. This enables precise and rapid identification of infectious agents, which is crucial for timely and effective treatment.
3. Clinical Research:
In collaboration with academic institutions and clinical research organizations, CytoDyn facilitates clinical research services. This includes designing, conducting, and managing clinical trials aimed at developing and testing new drugs and therapies, thereby advancing the field of biotechnology and improving patient care.
Conclusion
CytoDyn Inc. exemplifies a commitment to innovative research and development within the fields of immunotherapy and clinical diagnostics. Through its focused segments, cutting-edge products, and diverse services, the company addresses a broad spectrum of health conditions, aiming to transform the landscape of treatment for chronic diseases such as HIV, cancer, and autoimmune disorders. By continually advancing its portfolio, CytoDyn plays a crucial role in enhancing therapeutic options available to patients around the globe.
Segments
1. HIV/AIDS:
This segment is primarily engaged in the development of immunotherapy drugs aimed at curing HIV infection. The focus is on targeting and neutralizing HIV-infected cells, thereby improving patient outcomes and quality of life for those living with the virus.
2. Oncology:
CytoDyns oncology segment specializes in immunotherapies targeting various types of cancer, including but not limited to breast cancer, pancreatic cancer, and colorectal cancer. The overarching goal is to develop treatments that enhance the bodys immune response against tumors, thereby potentially reducing cancer metastasis and improving survival rates.
3. Immunology:
This segment is dedicated to addressing autoimmune diseases, which occur when the immune system mistakenly attacks healthy cells. CytoDyn aims to develop therapies for conditions such as Crohns disease, psoriasis, and multiple sclerosis, focusing on modulating the immune response to alleviate symptoms and prevent disease progression.
Products
1. PRO 140:
PRO 140 is a unique monoclonal antibody designed to target and block the CCR5 receptor found on T-cells. This mechanism is significant because the CCR5 receptor is utilized by HIV to enter and infect these immune cells. By inhibiting this entry pathway, PRO 140 has the potential to serve as a therapeutic option for managing HIV infection. As of now, it is undergoing phase III clinical trials to assess its efficacy and safety in treating HIV.
2. Leronlimab:
Leronlimab is another monoclonal antibody from CytoDyn that specifically blocks the CCR5 receptor, but in this context, it is aimed at cancer treatment. By inhibiting the receptors activity in cancer cells, Leronlimab seeks to prevent their growth and spread, offering a promising avenue for cancer care. It is currently in phase II clinical trials for various malignancies.
3. CytoFLEX:
CytoFLEX represents an advanced flow cytometry technology developed by CytoDyn, enabling the simultaneous analysis of up to 13 different parameters at high speed. This capability is vital for single-cell analysis in clinical research, allowing for intricate insights into cellular behaviors and responses in various health conditions.
Services
1. Contract Manufacturing:
CytoDyn provides contract manufacturing services to produce clinical-grade monoclonal antibodies and proteins. Their offerings in this area include a full spectrum of services from product formulation and optimization through to scaling up for larger production needs, supporting both clinical and research applications.
2. Diagnostic Testing:
The company also offers diagnostic testing services for various infectious diseases, employing sophisticated flow cytometry technology. This enables precise and rapid identification of infectious agents, which is crucial for timely and effective treatment.
3. Clinical Research:
In collaboration with academic institutions and clinical research organizations, CytoDyn facilitates clinical research services. This includes designing, conducting, and managing clinical trials aimed at developing and testing new drugs and therapies, thereby advancing the field of biotechnology and improving patient care.
Conclusion
CytoDyn Inc. exemplifies a commitment to innovative research and development within the fields of immunotherapy and clinical diagnostics. Through its focused segments, cutting-edge products, and diverse services, the company addresses a broad spectrum of health conditions, aiming to transform the landscape of treatment for chronic diseases such as HIV, cancer, and autoimmune disorders. By continually advancing its portfolio, CytoDyn plays a crucial role in enhancing therapeutic options available to patients around the globe.